Sanara MedTech vs Xtant Medical
SMTI and XTNT side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SMTI and XTNT compare
Sanara MedTech is the larger company, worth 10 times as much as Xtant Medical ($301M against $29.4M).
Sanara MedTech grew revenue faster over the last twelve months (13.0% versus −14.3% for Xtant Medical).
Xtant Medical keeps more of each dollar of sales as profit, with a net margin of −10.2% compared with −29.2% at Sanara MedTech.
Xtant Medical scores higher on the StockData Score (9 against 6 for Sanara MedTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SMTI | XTNT |
|---|---|---|
| Size and price | ||
| Market cap | $301M | $29.4M |
| Share price | $32.76 | $0.210 |
| Change, 1 year | 67.1% | −68.2% |
| Change, 5 years | 14.3% | −73.2% |
| Beta (5Y) | 1.43 | 0.07 |
| Employees | 108 | 151 |
| StockData Score | ||
| Total score | 6 | 9 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.7× | 0.3× (better) |
| P/B | 37.9× | 0.7× (better) |
| EV/EBITDA | 30.5× | – |
| P/FCF | 66.8× | – |
| FCF yield | 1.5% (better) | −2.4% |
| Fair value | $13.59 | $1.03 |
| Margin of safety | −141% | 79.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.0% (better) | −14.3% |
| Revenue growth, 5Y average | 45.9% (better) | 20.2% |
| Profitability | ||
| Gross margin | 93.0% (better) | 59.4% |
| Operating margin | 7.7% (better) | −9.6% |
| Net margin | −29.2% | −10.2% (better) |
| FCF margin | 4.1% (better) | −0.64% |
| Return on equity | −148% | −25.2% (better) |
| Return on invested capital | 13.1% (better) | −15.8% |
| Financial health | ||
| Debt / equity | 5.85 | 0.28 (better) |
| Net debt / EBITDA | 2.85 | – |
| Interest coverage | 1.2× (better) | −3.8× |
| Current ratio | 2.58 (better) | 2.16 |
| Altman Z-score | 3.77 (better) | −2.78 |
| Piotroski F-score | 3 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 19.4% | 106% |
| Held by insiders | 14.9% | – |
| Short interest, % of float | 5.3% | – |
Go deeper
- SMTI stock overview
- SMTI income statement
- SMTI valuation and score
- XTNT stock overview
- XTNT income statement
- XTNT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.